vs
Enact Holdings, Inc.（ACT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$312.7M vs $207.3M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 3.6%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ACT vs RARE — 直观对比
营收规模更大
ACT
是对方的1.5倍
$207.3M
营收增速更快
RARE
高出22.3%
3.6%
两年增速更快
RARE
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 71.3% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 3.6% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $1.23 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTRARE
| Q4 25 | $312.7M | $207.3M | ||
| Q3 25 | $311.5M | $159.9M | ||
| Q2 25 | $304.9M | $166.5M | ||
| Q1 25 | $306.8M | $139.3M | ||
| Q4 24 | $301.8M | $164.6M | ||
| Q3 24 | $309.6M | $139.5M | ||
| Q2 24 | $298.8M | $147.0M | ||
| Q1 24 | $291.6M | $108.8M |
净利润ACTRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | — | $-180.4M | ||
| Q2 25 | — | $-115.0M | ||
| Q1 25 | — | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | — | $-133.5M | ||
| Q2 24 | — | $-131.6M | ||
| Q1 24 | — | $-170.7M |
营业利润率ACTRARE
| Q4 25 | 71.3% | -54.7% | ||
| Q3 25 | 67.4% | -106.9% | ||
| Q2 25 | 70.4% | -64.8% | ||
| Q1 25 | 68.9% | -102.6% | ||
| Q4 24 | 68.9% | -74.3% | ||
| Q3 24 | 74.1% | -94.6% | ||
| Q2 24 | 78.6% | -79.1% | ||
| Q1 24 | 70.6% | -151.9% |
净利率ACTRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | — | -112.8% | ||
| Q2 25 | — | -69.0% | ||
| Q1 25 | — | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | — | -95.7% | ||
| Q2 24 | — | -89.5% | ||
| Q1 24 | — | -156.8% |
每股收益（稀释后）ACTRARE
| Q4 25 | $1.23 | $-1.28 | ||
| Q3 25 | $1.10 | $-1.81 | ||
| Q2 25 | $1.11 | $-1.17 | ||
| Q1 25 | $1.08 | $-1.57 | ||
| Q4 24 | $1.05 | $-1.34 | ||
| Q3 24 | $1.15 | $-1.40 | ||
| Q2 24 | $1.16 | $-1.52 | ||
| Q1 24 | $1.01 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $421.0M |
| 总债务越低越好 | $744.5M | — |
| 股东权益账面价值 | $5.4B | $-80.0M |
| 总资产 | $6.9B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTRARE
| Q4 25 | $582.5M | $421.0M | ||
| Q3 25 | $545.6M | $202.5M | ||
| Q2 25 | $616.0M | $176.3M | ||
| Q1 25 | $639.0M | $127.1M | ||
| Q4 24 | $602.8M | $174.0M | ||
| Q3 24 | $674.9M | $150.6M | ||
| Q2 24 | $711.3M | $480.7M | ||
| Q1 24 | $624.3M | $112.3M |
总债务ACTRARE
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — | ||
| Q1 24 | $746.1M | — |
股东权益ACTRARE
| Q4 25 | $5.4B | $-80.0M | ||
| Q3 25 | $5.3B | $9.2M | ||
| Q2 25 | $5.2B | $151.3M | ||
| Q1 25 | $5.1B | $144.2M | ||
| Q4 24 | $5.0B | $255.0M | ||
| Q3 24 | $5.0B | $346.8M | ||
| Q2 24 | $4.8B | $432.4M | ||
| Q1 24 | $4.7B | $140.3M |
总资产ACTRARE
| Q4 25 | $6.9B | $1.5B | ||
| Q3 25 | $6.9B | $1.2B | ||
| Q2 25 | $6.8B | $1.3B | ||
| Q1 25 | $6.7B | $1.3B | ||
| Q4 24 | $6.5B | $1.5B | ||
| Q3 24 | $6.6B | $1.5B | ||
| Q2 24 | $6.3B | $1.6B | ||
| Q1 24 | $6.3B | $1.3B |
负债/权益比ACTRARE
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流ACTRARE
| Q4 25 | $724.5M | $-99.8M | ||
| Q3 25 | $192.0M | $-91.4M | ||
| Q2 25 | $119.5M | $-108.3M | ||
| Q1 25 | $226.7M | $-166.5M | ||
| Q4 24 | $686.3M | $-79.3M | ||
| Q3 24 | $188.1M | $-67.0M | ||
| Q2 24 | $144.7M | $-77.0M | ||
| Q1 24 | $187.3M | $-190.7M |
自由现金流ACTRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率ACTRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度ACTRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
